Recombinant design of the enzymatically active domain of phage Enc34 endolysin to improve its activity against Gram-negative bacteria.

Publisher: Oxford University Press Country of Publication: England NLM ID: 7705721 Publication Model: Print Cited Medium: Internet ISSN: 1574-6968 (Electronic) Linking ISSN: 03781097 NLM ISO Abbreviation: FEMS Microbiol Lett Subsets: MEDLINE

Publication: 2015- : Oxford Oxford University Press
Original Publication: Amsterdam, Published by Elsevier/North Holland on behalf of the Federation of European Microbiological Societies.

Endopeptidases*/genetics ; Endopeptidases*/pharmacology ; Endopeptidases*/chemistry ; Endopeptidases*/metabolism ; Gram-Negative Bacteria*/drug effects ; Escherichia coli*/genetics ; Escherichia coli*/drug effects ; Bacteriophages*/genetics ; Bacteriophages*/enzymology ; Anti-Bacterial Agents*/pharmacology ; Anti-Bacterial Agents*/chemistry; Recombinant Fusion Proteins/genetics ; Recombinant Fusion Proteins/pharmacology ; Recombinant Fusion Proteins/chemistry ; Recombinant Fusion Proteins/metabolism ; Catalytic Domain ; Antimicrobial Peptides/pharmacology ; Antimicrobial Peptides/chemistry ; Antimicrobial Peptides/genetics ; Recombinant Proteins/genetics ; Recombinant Proteins/metabolism ; Recombinant Proteins/pharmacology ; Recombinant Proteins/chemistry

Endolysins are bacteriophage-encoded peptidoglycan-degrading enzymes with potential applications for treating multidrug-resistant bacterial infections. While exogenously applied endolysins are active against Gram-positive bacteria in their native form, Gram-negative bacteria are protected from such activity of most native endolysins by an outer membrane. However, it was shown that recombinant endolysins can be designed to efficiently lyse Gram-negative bacteria from without as well. During our previous efforts, we purified and structurally characterized the enzymatically active domain (EAD) of phage Enc34 endolysin. In this work, we investigated the lytic potential of products resulting from different variants of fusions involving this EAD with a panel of selected antimicrobial peptides. A set of constructs was generated and expressed in Escherichia coli cells. While most such recombinant proteins accumulated intracellularly, some of them could lyse cells from within and appear in the expression medium. The fusion protein variants produced were purified and tested for their bactericidal activity against Gram-negative bacteria. The best candidate caused rapid degradation of E. coli XL1-Blue cells during the first minutes after addition, reducing the viable cell count more than three-fold. We believe that these results might be helpful in the design of new antibacterial tools.
(© The Author(s) 2024. Published by Oxford University Press on behalf of FEMS.)

Int J Mol Sci. 2023 Jan 17;24(3):. (PMID: 36768143)
Biopolymers. 1995;37(2):105-22. (PMID: 7893944)
Front Microbiol. 2016 Sep 07;7:1402. (PMID: 27656173)
Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4107-12. (PMID: 11259652)
Int J Med Microbiol. 2010 Aug;300(6):357-62. (PMID: 20452280)
Science. 1988 Oct 21;242(4877):423-6. (PMID: 3140379)
Sci Rep. 2020 Jul 21;10(1):12087. (PMID: 32694655)
Front Microbiol. 2018 May 18;9:1033. (PMID: 29867909)
Nucleic Acids Res. 2016 Jan 4;44(D1):D1087-93. (PMID: 26602694)
J Virol. 2012 Oct;86(20):11403-4. (PMID: 22997422)
Antimicrob Agents Chemother. 2015 Apr;59(4):1983-91. (PMID: 25605353)
J Virol. 2024 Mar 19;98(3):e0173123. (PMID: 38329345)
J Appl Microbiol. 2011 Mar;110(3):778-85. (PMID: 21241420)
Sci Adv. 2020 Jun 03;6(23):eaaz1136. (PMID: 32537492)
Front Microbiol. 2022 May 03;13:888525. (PMID: 35722306)
Case Rep Dermatol. 2017 May 22;9(2):19-25. (PMID: 28611631)
Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1221-5. (PMID: 8577744)
Adv Exp Med Biol. 2019;1148:233-253. (PMID: 31482502)
Sci Rep. 2022 Mar 23;12(1):5005. (PMID: 35322067)
Biochim Biophys Acta Biomembr. 2019 Jul 1;1861(7):1375-1387. (PMID: 30926365)
Infect Immun. 2000 May;68(5):2748-55. (PMID: 10768969)
Int J Mol Sci. 2021 Oct 22;22(21):. (PMID: 34768832)
Adv Drug Deliv Rev. 2013 Oct;65(10):1357-69. (PMID: 23026637)
Nat Biotechnol. 2022 Jun;40(6):921-931. (PMID: 35241840)
Appl Microbiol Biotechnol. 2011 Apr;90(2):529-39. (PMID: 21264466)
PLoS One. 2012;7(5):e36991. (PMID: 22615864)
Enzyme Microb Technol. 2019 Sep;128:40-48. (PMID: 31186109)
Viruses. 2019 Mar 18;11(3):. (PMID: 30889807)
BMC Microbiol. 2018 Jun 5;18(1):54. (PMID: 29871599)
Int J Pept. 2013;2013:675391. (PMID: 23935642)
Biochimie. 2011 Jun;93(6):981-7. (PMID: 21396976)
Int J Antimicrob Agents. 2018 Mar;51(3):528-529. (PMID: 28843823)
Molecules. 2020 Dec 24;26(1):. (PMID: 33374458)
Nucleic Acids Res. 2023 Jan 6;51(D1):D733-D743. (PMID: 36399502)
Antibiotics (Basel). 2021 Jan 28;10(2):. (PMID: 33525684)
Front Microbiol. 2020 Oct 16;11:582779. (PMID: 33178164)
Peptides. 2010 Oct;31(10):1806-10. (PMID: 20603168)
Nat Commun. 2020 Jun 23;11(1):3184. (PMID: 32576824)

lzp-2021/1-0050 Latvian Council of Science

Keywords: Gram-negative bacteria; antibacterial tools; antimicrobial peptides; enzymatically active domain; peptidoglycan; phage Enc34 endolysin

EC 3.4.- (Endopeptidases)
EC 3.4.99.- (endolysin)
0 (Anti-Bacterial Agents)
0 (Recombinant Fusion Proteins)
0 (Antimicrobial Peptides)
0 (Recombinant Proteins)

Date Created: 20241214 Date Completed: 20241219 Latest Revision: 20250104

20250104

PMC11657235

10.1093/femsle/fnae103

39673269